35431 membres inscrits Accès abonné revues  Aide   Newsletter    Me connecter
Les Communiqués
 
 
     Nasdaq OMX
 
Rechercher dans le flux Nasdaq GlobeNewswire
Rechercher
Sanofi annonce l'approbation par la FDA d'AdlyxinTM dans le traitement du diabète de type 2 chez l'adulte
Wed, 27 07 2016 23:44:08
Sanofi annonce l'approbation par la FDA d'Adlyxin TM dans le traitement du diabète de type 2 chez l'adulte - Adlyxin TM est approuvé sous le nom de Lyxumia ® dans plus de 60 (...)
Sanofi Receives FDA Approval of AdlyxinTM for Treatment of Adults with Type 2 Diabetes
Wed, 27 07 2016 23:44:08
Sanofi Receives FDA Approval of Adlyxin TM for Treatment of Adults with Type 2 Diabetes - Adlyxin TM is approved as Lyxumia ® in more than 60 countries - Paris, France - (...)
Unique Brain Exercise Shown in Study to Lower Risk of Dementia
Wed, 27 07 2016 19:18:18
SAN FRANCISCO, July 27, 2016 (GLOBE NEWSWIRE) -- Researchers announced breakthrough study results Monday -- indicating that a particular form and dose of brain training can reduce the risk of dementia by 48 percent over a ten-year period in (...)
REALITY Trial Enrolls First Patient in Study Evaluating Medtronic Directional Atherectomy and Drug-Coated Balloon in PAD Treatment
Wed, 27 07 2016 19:15:00
VIVA Sponsored REALITY Study Assessing Vessel Preparation and Treatment in Severe Calcified Lesions Expands to Germany; Principal Investigators Named; First Patient Enrolled DUBLIN and SAN JOSE, Calif. -July 27, 2016 - (...)
uniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B Demonstrating up to 9 Months of Sustained Levels of Factor IX Activity and Therapeutic Effect
Wed, 27 07 2016 18:15:00
--Data from Low-Dose Cohort of AMT-060 Clinical Trial Continues to Show Durability and Therapeutically Relevant Factor IX (FIX) Activity in Severe, Older Patients with Advanced Joint Disease and Frequent Bleeding Episodes-- --Four Patients Remain (...)
Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine
Wed, 27 07 2016 13:00:00
COPENHAGEN, Denmark, July 27, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the initiation of a Phase 1 clinical trial of MVA-BN YF, a new vaccine candidate based on the Company's proprietary MVA-BN platform, (...)
Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon
Wed, 27 07 2016 11:00:00
SAN DIEGO, July 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Republic of Lebanon Ministry of Public Health (...)
Addex ADX71441 Demonstrates Positive Results in Highly Translational Preclinical Model of Spasticity.
Wed, 27 07 2016 05:00:00
Geneva, Switzerland, 27 July 2016 - Addex Therapeutics (SIX: ADXN) announced today that ADX71441, a positive allosteric modulator (PAM) of the GABAB receptor demonstrated positive results in a highly translational preclinical model of (...)
Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma
Tue, 26 07 2016 12:00:00
PHILADELPHIA and OXFORD, United Kingdom, July 26, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that the European Commission has designated the (...)
RedHill Biopharma Reports 2016 Second Quarter Financial Results
Tue, 26 07 2016 11:00:00
RedHill maintains a strong and debt-free balance sheet with $47.7 million in cash at the end of the second quarter, allowing the Company to continue to diligently execute its three ongoing Phase III gastrointestinal disease (...)
Les résultats d'une enquête internationale publiés par l'ISAPS font état d'une augmentation de plus d'un million d'interventions en chirurgie esthétique et reconstructive effectuées en 2015
Tue, 26 07 2016 08:00:00
Le monde continue à apprécier la chirurgie plastique et esthétique, comme l'indique le nombre croissant d'interventions. NEW YORK, le 26 juillet 2016 (GLOBE NEWSWIRE) - La portée mondiale de la Société Internationale de Chirurgie (...)
Global Survey Released by ISAPS Reports Increase of Over One Million Cosmetic and Aesthetic Procedures Performed in 2015
Tue, 26 07 2016 08:00:00
The world continues to find value in aesthetic plastic surgery as indicated by growing numbers of procedures. NEW YORK, July 26, 2016 (GLOBE NEWSWIRE) -- The worldwide reach of the International Society of Aesthetic Plastic Surgery (ISAPS) is well (...)
Immunicum announces that a patent application in China regarding the Company's CD70-technology will be granted
Tue, 26 07 2016 07:01:19
Gothenburg, Sweden, July 26, 2016. Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that (...)
Orion Corporation: Announcement of transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons
Tue, 26 07 2016 07:00:00
ORION CORPORATION STOCK EXCHANGE RELEASE 26 JULY 2016 at 10.00 a.m. EEST Person subject to the notification requirement Name: Ahomäki, Satu  Position: Other senior (...)
Invitation to Valmet's Capital Markets Day in Helsinki on September 20, 2016
Tue, 26 07 2016 06:45:00
Valmet Oyj's stock exchange release on July 26, 2016 at 9:45 a.m. EET Valmet invites analysts and institutional investors to its Capital Markets Day in Helsinki on Tuesday, September 20, 2016. The event will start at 9:00 a.m. (EET) and end (...)
Bio-plastic Minerv-PHA developed by Bio-on now available in Material ConneXion's database
Tue, 26 07 2016 05:45:00
THE INNOVATIVE BIO-ON MATERIAL MINERV-PHA HAS BEEN ACCEPTED INTO THE MATERIAL CONNEXION LIBRARY Bologna, July 26 th 2016 - From today the cutting-edge bio-plastic Minerv-PHA developed by Bio-on is (...)
XBiotech fait le point sur les Programmes Xilonix(TM) de Phase III aux États-Unis et dans l'UE
Mon, 25 07 2016 22:57:50
AUSTIN, Texas, le 26 juillet 2016 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ : XBIT), développeur des thérapies par anticorps True Human(TM) de la prochaine génération, a déclaré aujourd'hui que l'Independent Data Monitoring Committee (...)
PCI Biotech receives positive opinion for Orphan Drug Designation of fimaporfin for treatment of cholangiocarcinoma in EU
Mon, 25 07 2016 18:46:44
Oslo, 25 July 2016 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that it has received a positive opinion from the European Medicine Agency's (EMA) Committee for Orphan Medicinal Products (COMP) for its (...)
Ossur Hf :Transactions in relation to share buyback program
Mon, 25 07 2016 16:00:00
Announcement from Össur hf. No. 72/2016 Reykjavík, 25 July 2016 On 3 December 2015, Össur hf. initiated a share buy-back program, see Company announcement no. 48/2015. The purpose of the share buyback program is to (...)
VALNEVA Announces Successful Completion of Phase II for Clostridium Difficile Vaccine Candidate
Mon, 25 07 2016 15:45:00
Valneva Announces Successful Completion of Phase II  for Clostridium Difficile Vaccine Candidate Final Phase II results of Valneva's Clostridium difficile vaccine candidate confirm positive initial Phase II (...)
VALNEVA annonce des résultats de fin de Phase II positifs pour son candidat vaccin contre le Clostridium difficile
Mon, 25 07 2016 15:45:00
Valneva annonce des résultats de fin de Phase II positifs pour son candidat vaccin contre le Clostridium difficile Les résultats de fin de Phase II du candidat vaccin contre le Clostridium difficile de Valneva (...)
Agfa-Gevaert : Publication of a transparency notification - Regulated information (Article 14 of the law of May 2, 2007 on the disclosure of significant shareholdings)
Mon, 25 07 2016 15:40:00
Mortsel , Belgium - July 25, 2016 - 5.40 p.m. CET According to Agfa-Gevaert NV's bylaws, the threshold as from which a shareholding needs to be disclosed, has been set at 3%, 5% and a multiple of 5%. In (...)
MorphoSys to Host Q2 2016 Conference Call on August 1, 2016
Mon, 25 07 2016 12:00:00
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first six months' 2016 results on August 1, 2016 at 7:00 am CEST. At 2:00 pm CEST (1:00 pm BST, 8:00 am EDT), the Management Board of MorphoSys AG will host a (...)
Apricus Biosciences, Inc. : Apricus Biosciences Further Expands Existing Vitaros® Partnership with Ferring Pharmaceuticals in Europe and Asia
Mon, 25 07 2016 11:00:00
Apricus Eligible to Receive an Additional $3.6 Million in Upfront and Pre-Commercialization Milestone Payments for the Expanded Territory Apricus and Sandoz Agree to Mutually Terminate License Agreement SAN DIEGO, July (...)
Novo Nordisk A/S - Share repurchase programme
Mon, 25 07 2016 08:46:23
  Bagsværd, Denmark, 25 July 2016 - On 29 April 2016, Novo Nordisk initiated a share repurchase programme under the provisions of the European Commission's regulation no. 2273/2003 of 22 December 2003 and in accordance with Article 5 (...)
publicités
publicité
 
  KauriWeb

Afficher toutes les thématiques